Genetic Basis and Pathophysiology of Huntington’s Disease

Genetic Mechanism

• Huntington’s disease is caused by an expanded CAG trinucleotide repeat (≥ 40 repeats) in exon 1 of the HTT gene on chromosome 4p16.3, producing an abnormally long polyglutamine tract that leads to protein misfolding, toxic aggregation, and selective neuronal death in the striatum【1】.
• The HTT gene spans approximately 170 kb, contains 67 exons, and encodes a ~3,144‑amino‑acid huntingtin protein (~350 kDa) that normally functions as a housekeeping protein【1】.
• Normal alleles most commonly contain 17–19 CAG repeats; alleles with ≤ 26 repeats are never associated with disease【1】【2】.
• Alleles with ≥ 40 repeats demonstrate full penetrance and 100 % diagnostic specificity, whereas alleles with 36–39 repeats show reduced penetrance and variable clinical expression【1】.
• The mutation follows an autosomal‑dominant inheritance pattern; the expanded allele is meiotically unstable and can further expand during transmission, especially via paternal inheritance【1】【3】.

Molecular Pathogenesis

• The expanded polyglutamine tract causes the mutant huntingtin protein to misfold and adopt abnormal conformations, initiating toxic gain‑of‑function mechanisms【2】.
• Proteolytic cleavage generates N‑terminal fragments that retain the polyglutamine expansion and are especially prone to aggregation; these fragments accumulate as intranuclear inclusions in neurons of affected individuals【2】.
• Altered post‑translational modifications of huntingtin affect its function and degradation, contributing to cellular toxicity【2】.

Selective Neurodegeneration Pattern

• Despite ubiquitous expression of mutant huntingtin, neurodegeneration is highly selective for the caudate nucleus and putamen (striatum) — the primary sites of neuronal loss in Huntington’s disease【1】【3】【2】.

Clinical Manifestations Linked to Pathology

• Striatal degeneration produces choreic (involuntary) movements by disrupting motor‑control circuits【1】.
• Progressive loss of neurons in basal ganglia and their cortical connections underlies cognitive decline【1】.
• Involvement of limbic and cortical networks leads to psychiatric manifestations such as behavioral changes and affective symptoms【1】.
• Early‑onset Huntington’s disease (onset before adulthood) is characterized by rigidity, spasticity, and rapid intellectual decline, accounting for roughly 5 % of cases【1】.

Diagnostic Implications

• The CAG repeat expansion accounts for > 99 % of Huntington’s disease cases, rendering genetic testing highly sensitive and specific for diagnosis【2】.

Transmission Risk for Intermediate Alleles

• Alleles with 27–35 CAG repeats (intermediate range) do not cause disease in carriers but carry a 6–10 % risk of expanding to a pathogenic length when transmitted paternally, with the highest risk at the upper end of the range (≈ 35 repeats)【3】【2】.

Huntington Disease Diagnosis and Management

Disease Classification and Mechanism

• The American College of Medical Genetics and Genomics states that Huntington disease is classified as a hereditary neurodegenerative disease, caused by an abnormal expansion of CAG repeats (≥40 repeats for full penetrance) in exon 1 of the HTT gene, leading to toxic protein aggregation and neuronal death 4, 5
• The disease mechanism involves direct neurotoxicity from mutant huntingtin protein, causing progressive neurodegeneration over 15-20 years, with no immune system involvement 5, 6
• The European Journal of Human Genetics recommends genetic testing as a diagnostic tool, measuring CAG repeat length, which confirms diagnosis with 100% specificity for alleles ≥40 repeats 4, 6

Clinical Implications

• The International Parkinson and Movement Disorder Society states that immunosuppressive therapies have no role in HD management, as the disease is not autoimmune in nature 7
• The American Academy of Neurology recommends current treatment to be purely symptomatic, using dopamine-depleting agents for chorea and antipsychotics for behavioral symptoms 7, 8
• The National Institute of Neurological Disorders and Stroke reports that future therapies target the genetic defect, including gene silencing with antisense oligonucleotides, RNA interference, and gene editing approaches, which are in clinical trials 9, 7

Genetic and Molecular Basis of Huntington’s Disease

Genetic Characteristics

• The HTT gene spans ~170 kb, contains 67 exons, and encodes a ~350 kDa huntingtin protein composed of 3,144 amino acids. 10
• Normal alleles carry 17–19 CAG repeats and never cause disease, whereas alleles with ≥40 repeats have full penetrance and >99 % diagnostic specificity for Huntington’s disease. 10
• The disorder follows an autosomal‑dominant inheritance pattern; paternal transmission is especially unstable, with intermediate alleles (27–35 repeats) having a 6–10 % chance of expanding to a pathogenic length in the next generation. 10
• Reduced‑penetrance alleles (36–39 repeats) display variable clinical expression; not all carriers develop symptoms, but they remain meiotically unstable. 10

Molecular Pathogenesis

• Expansion of the CAG repeat produces an abnormally long polyglutamine tract that confers a toxic gain‑of‑function to mutant huntingtin, driving neurodegeneration. [11][12]
• The polyQ stretch induces misfolding of huntingtin, generating N‑terminal fragments that readily aggregate and resist clearance by lysosomal and ubiquitin‑proteasome pathways. [11][12]
• Misfolded huntingtin and its fragments accumulate as intranuclear inclusions in neurons, where they aberrantly interact with other proteins and disrupt normal cellular functions. [10][11]12

Cellular Dysfunction Mechanisms

• Proteostasis disruption: Mutant huntingtin impairs protein quality‑control systems, leading to accumulation of damaged proteins. [11][12]
• Nuclear pore complex dysfunction: Aberrant huntingtin interferes with nucleocytoplasmic transport, compromising nuclear integrity. [11][12]
• Transcriptional dysregulation: Mutant protein alters gene‑expression programs, affecting neuronal survival pathways. [11][12]
• Mitochondrial dysfunction: Energy production is reduced and reactive oxygen species are increased, contributing to neuronal injury. [11][12]
• Axonal transport defects: Intracellular trafficking of organelles and vesicles is disrupted, impairing neuronal connectivity. [11][12]
• Synaptic signaling abnormalities: Neurotransmission is compromised, leading to functional deficits in basal‑ganglia circuits. [11][12]
• Altered post‑translational modifications: Mutant huntingtin undergoes abnormal processing that further impairs its degradation and function. 10

Selective Neurodegeneration Pattern

• Although mutant huntingtin is expressed throughout the brain, neuronal loss is most pronounced in the caudate nucleus and putamen (striatum), the primary sites of clinical manifestation. 10
• Additional brain regions—including other basal‑ganglia structures, hypothalamus, cortex, and brain stem—are also affected to a lesser extent. 10

Clinical Implications of Genetic Findings

• Intermediate alleles (27–35 repeats) do not cause disease in carriers but pose a transmission risk, especially via paternal inheritance; clinicians should counsel families accordingly. 10
• Reduced‑penetrance alleles (36–39 repeats) may or may not lead to symptom onset; surveillance strategies should be individualized based on family history and repeat length. 10